Jun. 13 at 9:42 AM
$IPHA Innate Pharma presents preclinical data for IPH6501 at EHA
Innate Pharma announced the presentation of preclinical data for IPH6501, its proprietary Anket targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory B-cell non-Hodgkin lymphoma, at the European Hematology Association Congress 2025, taking place June 12-15 in Milan, Italy. R-CHOP is an established standard of care for treatment-naive patients with diffuse large B cell lymphoma and follicular lymphoma, two subtypes of B-NHL.
The treatment landscape continues to evolve with novel approaches including T cell engagers, antibody-drug conjugates, their combination with standard of care therapies, and CAR-T cells. Yet, there remains an unmet medical need for patients ineligible, refractory to, or relapsing from these therapies. In preclinical in vitro models, IPH6501 demonstrated potent NK cell proliferation and tumor cell killing activity in DLBCL and FL patient samples, supporting its therapeutic potential in these indications.
In preclinical in vivo xenografted mouse tumor models, IPH6501 showed strong activity in a rituximab-resistant model - even in the presence of rituximab highlighting their combination potential. Additionally, when combined with R-CHOP, IPH6501 showed enhanced antitumor efficacy, leading to tumor eradication that was maintained after treatment discontinuation.
These findings underscore the potential of IPH6501 in improving standard-of-care R-CHOP treatment in previously untreated DLBCL and FL patients and support further evaluation of additional combination strategies in B-NHL.
